Skip to main content
Premium Trial:

Request an Annual Quote

European Consortium Awarded Nearly $4M to Develop Plasma Biomarker Discovery Platform

NEW YORK (GenomeWeb News) – A consortium of European companies and universities has been awarded €3 million ($3.8 million) under the European Commission's 7th Framework Program to develop a plasma biomarker discovery platform.

The three-year project, called Proactive, will be coordinated by Olink Bioscience of Uppsala, Sweden. Other partners include Innova Biosciences, Copenhagen University, Fujirebio Diagnostics, Uppsala University, and Integromics.

The goal of the initiative is to develop methods and reagents for multiplexed proximity ligation assays for detecting low-abundance proteins in plasma, along with statistical methods and data-management tools. The participants plan to carry out a series of pilot biomarker projects focused on colorectal cancer detection in blood samples.

The participants plan to develop a platform that can analyze 100 samples per week. The platform will be able to detect 180 putative protein biomarkers using four microliters of plasma, the participants said.

Further information about the project is available here.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.